OCUPHIRE PHARMA INC (OCUP) Stock Price & Overview
NASDAQ:OCUP • US67577R1023
Current stock price
The current stock price of OCUP is 1.17 USD. Today OCUP is down by -12.03%. In the past month the price decreased by -9.3%. In the past year, price decreased by -57.61%.
OCUP Key Statistics
- Market Cap
- 30.654M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.55
- Dividend Yield
- N/A
OCUP Stock Performance
OCUP Stock Chart
OCUP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OCUP. When comparing the yearly performance of all stocks, OCUP is a bad performer in the overall market: 95.77% of all stocks are doing better.
OCUP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to OCUP. OCUP has a great financial health rating, but its profitability evaluates not so good.
OCUP Earnings
On August 13, 2024 OCUP reported an EPS of -0.3 and a revenue of 1.11M. The company missed EPS expectations (-15.34% surprise) and missed revenue expectations (-55.68% surprise).
OCUP Forecast & Estimates
9 analysts have analysed OCUP and the average price target is 17.09 USD. This implies a price increase of 1360.26% is expected in the next year compared to the current price of 1.17.
For the next year, analysts expect an EPS growth of -85.94% and a revenue growth -44.06% for OCUP
OCUP Groups
Sector & Classification
OCUP Financial Highlights
Over the last trailing twelve months OCUP reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -165.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.46% | ||
| ROE | -34.71% | ||
| Debt/Equity | 0 |
OCUP Ownership
OCUP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 929.285B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 582.039B | ||
| MRK | MERCK & CO. INC. | 22.34 | 285.833B | ||
| PFE | PFIZER INC | 8.9 | 151.141B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.315B | ||
| ZTS | ZOETIS INC | 16.34 | 48.807B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.334B | ||
| VTRS | VIATRIS INC | 5.39 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.405B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.983B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.157B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.94B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.046B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCUP
Company Profile
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The firm is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Company Info
IPO: 2004-11-30
OCUPHIRE PHARMA INC
37000 Grand River Ave., Suite 120
Farmington Hills MICHIGAN 48335 US
CEO: Mina Sooch
Employees: 14
Phone: 12486819815
OCUPHIRE PHARMA INC / OCUP FAQ
What does OCUPHIRE PHARMA INC do?
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Company’s pipeline candidates include APX2009 and APX2014. The firm is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Can you provide the latest stock price for OCUPHIRE PHARMA INC?
The current stock price of OCUP is 1.17 USD. The price decreased by -12.03% in the last trading session.
What is the dividend status of OCUPHIRE PHARMA INC?
OCUP does not pay a dividend.
How is the ChartMill rating for OCUPHIRE PHARMA INC?
OCUP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for OCUPHIRE PHARMA INC?
OCUPHIRE PHARMA INC (OCUP) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for OCUP stock?
OCUPHIRE PHARMA INC (OCUP) currently has 14 employees.
What is OCUPHIRE PHARMA INC worth?
OCUPHIRE PHARMA INC (OCUP) has a market capitalization of 30.65M USD. This makes OCUP a Nano Cap stock.